Details of the Drug Pharmacogenomic Perturbation Atlas

Dronedarone Drug Info

Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide

Cross-matching ID

PubChem CID

208898

ChEBI ID

CHEMBL184412

CAS Number

CAS 141626-36-0

TTD Drug ID

D05CPV

VARIDT Drug ID

DR00531

INTEDE Drug ID

DR0550

ACDINA Drug ID

D00218

General Information of Drug (ID: DMA8FS5)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.23	0.00e+0	19/20 (95%)	SQLE;CYP51A1;TM7SF2;...
Regulation of lipolysis in adipocytes	2.05	1.04e-2	52/55 (94.55%)	GNAI1;FABP4;PLAAT3;...
Glycerolipid metabolism	1.83	4.51e-2	44/61 (72.13%)	ALDH2;DGKD;MGLL;...
Diabetic cardiomyopathy	-1.71	3.29e-2	162/203 (79.8%)	PPP1CB;ATP5MC3;PRKCD;...
Legionellosis	-1.72	3.52e-2	51/57 (89.47%)	ITGB2;CD14;HSPA1A;...
Alzheimer disease	-1.72	3.91e-2	279/369 (75.61%)	FRAT2;PSMC4;PSMA5;...
Amyotrophic lateral sclerosis	-1.72	4.40e-2	267/364 (73.35%)	PSMD1;PSMC3;CASP1;...
Parkinson disease	-1.83	1.77e-2	176/249 (70.68%)	PSMC4;PSMA5;ATP5MC3;...
Ribosome	-1.84	2.06e-2	113/158 (71.52%)	RPL32;RPL37A;RPLP0;...
Huntington disease	-1.84	2.48e-2	233/306 (76.14%)	COX6A1;ATP5MC1;PSMA3;...
Pathways of neurodegeneration	-1.85	3.09e-2	354/475 (74.53%)	NFKB1;BECN1;BCL2L1;...
Prion disease	-1.88	3.49e-2	209/273 (76.56%)	PSMC4;PSMA5;ATP5MC3;...
Proteasome	-1.91	4.28e-2	44/46 (95.65%)	PSMD1;PSMC3;PSMD7;...
Oxidative phosphorylation	-2.16	0.00e+0	93/133 (69.92%)	ATP6V0D1;ATP5MC3;ATP5F1D;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H